860457-92-7

Basic information

• Product Name: METHYL 3-BROMOINDOLE-6-CARBOXYLATE
• Synonyms: METHYL 3-BROMOINDOLE-6-CARBOXYLATE;Methyl 3-broMo-1H-indole-6-carboxylate;3-Bromo-1H-indole-6-carboxylic acid methyl ester;1H-Indole-6-carboxylic acid, 3-bromo-, methyl ester
• CAS NO: 860457-92-7
• Molecular Formula: C₁₀H₈BrNO₂
• Molecular Weight: 254.09
• Mol File: 860457-92-7.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 386.161°C at 760 mmHg
• Flash Point: 187.344°C
• Appearance: /
• Density: 1.629
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.666
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 14.13±0.30(Predicted)
• CAS DataBase Reference: METHYL 3-BROMOINDOLE-6-CARBOXYLATE(CAS DataBase Reference)
• NIST Chemistry Reference: METHYL 3-BROMOINDOLE-6-CARBOXYLATE(860457-92-7)
• EPA Substance Registry System: METHYL 3-BROMOINDOLE-6-CARBOXYLATE(860457-92-7)

Safety Data

• Hazardous Substances Data: 860457-92-7(Hazardous Substances Data)

Usage

General Description

Methyl 3-Bromoindole-6-carboxylate is a synthetic chemical compound that falls under the category of organobromides and indoles. Its molecular formula is C10H8BrNO2. It is generally used in the pharmaceutical industry and organic synthesis processes, often serving as an intermediate in drug production. Due to the complex nature of its structure, it allows for the creation of a diverse range of chemical species. Its properties and reactions are heavily dependent on its particular chemical makeup. This chemical is typically handled and studied in controlled environments due to its potential to be harmful if not handled properly.

InChI:InChI=1/C10H8BrNO2/c1-14-10(13)6-2-3-7-8(11)5-12-9(7)4-6/h2-5,12H,1H3

Upstream product

• 50820-65-0 indole-6-carboxylic acid methyl ester 

Downstream Products

• 1198591-92-2 1-[(4-{[(4-cyclohexylphenyl)carbonyl]amino}phenyl)methyl]-3-phenyl-1H-indole-6-carboxylic acid 
• 1198593-09-7 C₃₃H₃₉N₃O₃ 
• 1198593-07-5 methyl 2-[(methylamino)methyl]-1-[4-({[4-(1-methylethyl)phenyl]carbonyl}amino)butyl]-3-phenyl-1H-indole-6-carboxylate 
• 1198593-03-1 methyl 2-ethenyl-1-[4-({[4-(1-methylethyl)phenyl]carbonyl}amino)butyl]-3-phenyl-1H-indole-6-carboxylate 
• 1198592-88-9 methyl 3-(2-hydroxyphenyl)-1-[4-({[4-(1-methylethyl)phenyl]carbonyl}amino)butyl]-1H-indole-6-carboxylate 
• 1198593-11-1 methyl 3-(1-benzothien-2-yl)-1-{2-[(2-{[4-(1-methylethyl)phenyl]amino}-2-oxoethyl)oxy]ethyl}-1H-indole-6-carboxylate 
• 1198593-06-4 methyl 2-formyl-1-[4-({[4-(1-methylethyl)phenyl]carbonyl}amino)butyl]-3-phenyl-1H-indole-6-carboxylate 
• 1198593-00-8 methyl 1-[4-({[4-(dimethylamino)-2-hydroxyphenyl]carbonyl}amino)butyl]-3-(3-furanyl)-1H-indole-6-carboxylate 
• 1198593-02-0 methyl 2-bromo-1-[4-({[4-(1-methylethyl)phenyl]carbonyl}amino)butyl]-3-phenyl-1H-indole-6-carboxylate 
• 1198592-87-8 methyl 1-[4-({[4-(1-methylethyl)phenyl]carbonyl}amino)butyl]-3-[2-(methyloxy)phenyl]-1H-indole-6-carboxylate 
• 1198592-61-8 methyl 1-(2-{4-[4-(1-methylethyl)phenyl]-1-piperazinyl}-2-oxoethyl)-3-phenyl-1H-indole-6-carboxylate 
• 1198592-83-4 methyl 1-(2-aminoethyl)-3-phenyl-1H-indole-6-carboxylate hydrochloride 
• 1198591-51-3 1-[4-({[4-(1-methylethyl)phenyl]carbonyl}amino)butyl]-3-phenyl-1H-indole-6-carboxylic acid 
• 1198593-08-6 methyl 1-{2-[methyl(2-{[4-(1-methylethyl)phenyl]amino}-2-oxoethyl)amino]ethyl}-3-phenyl-1H-indole-6-carboxylate 

Relevant articles and documents

PGDH INHIBITORS AND METHODS OF MAKING AND USING

Disclosed herein are compounds that can inhibit 15-hydroxyprostaglandin dehydrogenase. Such compounds may be administered to subjects that may benefit from modulation of prostaglandin levels.

Discovery of Indole- and Indazole-acylsulfonamides as Potent and Selective NaV1.7 Inhibitors for the Treatment of Pain

3-Aryl-indole and 3-aryl-indazole derivatives were identified as potent and selective Nav1.7 inhibitors. Compound 29 was shown to be efficacious in the mouse formalin assay and also reduced complete Freund's adjuvant (CFA)-induced thermal hyper

ASH1L INHIBITORS AND METHODS OF TREATMENT THEREWITH

Provided herein are small molecule inhibitors of ASH1L activity and small molecules that facilitate ASH1L degradation and methods of use thereof for the treatment of disease, including acute leukemia, solid cancers and other diseases dependent on activity of ASH1L.